F-star updates on its collaboration with Denali

10 January 2018

Following the announcement of a collaboration between US biotech firm Denali Therapeutics (Nasdaq: DNLI) and Japan’s Takeda Pharmaceutical (TYO: 4502) to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases, UK biotech F-star has provided an update on its own collaboration with Denali.

These three therapeutic programs are based on Denali's ATV (Antibody Transport Vehicle) technology and include transferrin receptor-specific Fcabs (Fc-domains with antigen-binding activity) that were discovered under the August 2016 collaboration with F-star. This collaboration leverages F-star’s Modular Antibody Technology and Denali’s expertise in the development of therapeutics for neurological diseases. The collaboration is held within F-star Gamma Limited (F-star Gamma), an asset-centric vehicle in the F-star family.

F-star chief executive John Haurum commented: “Denali Therapeutics’ agreement with Takeda is extremely exciting news for F-star and provides clear validation of our technology. It underlines the positive progress in our collaboration.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK